Preterm Birth Prevention Overview

Principles

Definition

Preterm birth prevention is a critical area of biomedical and clinical research focused on identifying, understanding, and mitigating the factors contributing to births occurring before 37 weeks of gestation. This multidisciplinary field investigates biological, environmental, and social determinants, as well as pharmacological, surgical, and behavioral interventions, with the primary goal of reducing neonatal morbidity and mortality and improving long-term health outcomes.

Ontological type

Pharmacologic Interventions

Risk Stratification

Cervical Procedures

Key developments

Key Figures

Biological Risk Stratification era

Roberto Romero [1], affiliated with Harvard University [3] and New Haven Public Schools [4] during this era, emerged as a leading figure in biologically based preterm birth prevention. His work on Amniotic fluid interleukin 6 in preterm labor: Association with infection [7] highlighted intrapartum inflammation as a key risk factor and propelled biomarker-based risk stratification. K. H. Nicolaides [2], affiliated with University of Cambridge [5] and University College London [6] during this era, contributed pivotal randomized evidence through the paper Cervical cerclage for prevention of preterm delivery in woman with short cervix:randomised controlled trial [8]. Together, these contributions anchored biologically based risk stratification by linking inflammatory biomarkers and cervical length with preterm birth risk, enabling targeted prevention strategies in ambulatory and home settings.

Targeted Clinical Interventions era

Joy E Lawn [1] is a leading figure whose work at Johns Hopkins University [3] and the University of Washington [4] shaped preterm birth prevention in the 2006–2016 Targeted Clinical Interventions era. Her key contributions include Born too soon: the Global action report on preterm birth [7] and Preventing preterm births: analysis of trends and potential reductions with interventions in 39 countries with very high human development index [8], which advanced evidence-based, risk-stratified prevention and translation into practice. Kenneth J. Leveno [2] is a prominent figure linked to The University of Texas Southwestern Medical Center [5] and The University of Texas Health Science Center at San Antonio [6]. His contribution in this era centers on Optimizing Care and Outcome for Late-Preterm (Near-Term) Infants: A Summary of the Workshop Sponsored by the NICHD [9], which synthesized workshop findings to guide care protocols and translational efforts for late-preterm infants.

Integrated System-Level Prevention era

K. H. Nicolaides [1] is a leading figure in preterm birth prevention with affiliations at Harvard University [3] and Northwestern University [4] during this era. His contributions include the Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit [7], and Early vaginal progesterone versus placebo in twin pregnancies for the prevention of spontaneous preterm birth: a randomized, double-blind trial [8], which together advanced scalable pharmacologic prevention within health systems. D. Wright [2] is a prominent figure associated with University College London [5] and the Chinese University of Hong Kong [6] during this period. These two trials [7] and [8] illustrate Wright's contributions to the integrated prevention agenda, demonstrating how pharmacologic prevention within health-system frameworks can inform policy, guideline platforms, and cross-sector implementation in this era.